Roivant Sciences saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 69 to 74.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's unique RS Rating identifies technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks stacks up against all the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 in the early stages of their moves. See if Roivant Sciences can continue to show renewed price strength and clear that threshold.
Roivant Sciences is building a consolidation with a 13.05 buy point. See if it can clear the breakout price in heavy volume.
The company posted 0% earnings growth in the latest quarterly report, while sales growth came in at -42%.
Roivant Sciences earns the No. 125 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
